By Sarah Roden Gilead Sciences (NASDAQ: GILD) released first quarter 2015 earnings on April 30. High revenues pointed to the success of Gilead’s …
In a research report issued today, Needham analyst Alan Carr reiterated a Buy rating on Gilead Sciences, Inc. (NASDAQ:GILD) with a $120 price target, after …
Intercept Pharmaceuticals Inc (NASDAQ: ICPT) is a biopharmaceutical company known for developing drug treatments for chronic liver diseases. The company’s current leading drug is …
In a research report released Monday, Needham analyst Alan Carr reiterated a Buy rating on Intercept Pharmaceuticals Inc (NASDAQ:ICPT) with a price target of …
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is making headlines with the sudden announcement of the CEO’s retirement and an application delay for the company’s leading drug.
In a research report issued today, Needham analyst Alan Carr reiterated a Buy rating on Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) and reduced the price target to …
In a research report issued today, Needham analyst Alan Carr reiterated a Buy rating on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) with a $40 price target, after …
In a research report released today, Needham analyst Alan Carr maintained a Buy rating on Cempra (NASDAQ:CEMP) with a $42 price target, based on …
In a research report released today, Needham analyst Alan Carr maintained a Hold rating on VIVUS, Inc.(NASDAQ:VVUS), following the company’s fourth-quarter results, posting $12.
In a research report published Thursday, Needham analyst Alan Carr reiterated a Hold rating on VIVUS, Inc. (NASDAQ:VVUS), as the company is expected to announce …
